Antiplatelet Activity of Valproic Acid Contributes to Decreased Soluble CD40 Ligand Production in HIV Type 1-Infected Individuals
- 1 January 2011
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 186 (1) , 584-591
Abstract
CD40L is a type II membrane glycoprotein of the TNF family that is found on activated T cells, B cells, and platelets. We previously reported that the soluble form of this inflammatory mediator (sCD40L) is elevated in the plasma and cerebrospinal fluid of HIV-1–infected, cognitively impaired individuals. In this study, we demonstrate that the mood-stabilizing drug valproic acid (VPA) reduces sCD40L levels in plasma samples of HIV-1–infected patients (n = 23) and in washed human platelets, which are the main source of circulating sCD40L. VPA also inhibited HIV-1 transactivator of transcription-induced release of sCD40L and platelet factor 4 in C57BL/6 mice. The mechanism by which VPA was able to do so was investigated, and we demonstrate that VPA, a known glycogen synthase kinase 3β inhibitor, blocks platelet activating factor-induced activation of glycogen synthase kinase 3β in platelets in a manner that alters sCD40L release from platelets. These data reveal that VPA has antiplatelet activity, and they convey important implications for the potential of VPA as an adjunct therapy not only for cognitively impaired patients with HIV-1 infection, but also numerous inflammatory diseases for which such antiplatelet therapies are currently lacking.Keywords
This publication has 49 references indexed in Scilit:
- Dyad of CD40/CD40 Ligand Fosters Neuroinflammation at the Blood-Brain Barrier and Is Regulated via JNK Signaling: Implications for HIV-1 EncephalitisJournal of Neuroscience, 2010
- Platelets and Megakaryocytes Contain Functional Nuclear Factor-κBArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- 15-deoxy-Δ12,14-PGJ2 enhances platelet production from megakaryocytesBlood, 2008
- GSK3β is a negative regulator of platelet function and thrombosisBlood, 2008
- Recruitment of active glycogen synthase kinase-3 into neuronal lipid raftsBiochemical and Biophysical Research Communications, 2006
- Targeting CD40L: a Promising Therapeutic ApproachClinical and Vaccine Immunology, 2004
- Glycogen synthase kinase-3β is highly activated in nuclei and mitochondriaNeuroReport, 2003
- Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytesJournal of Cell Science, 2003
- Coagulation Abnormalities and Acquired von Willebrand's Disease Type 1 in Children Receiving Valproic AcidJournal of Child Neurology, 2002
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995